FAM25C Inhibitors
FAM25C inhibitors encompass a spectrum of molecules that directly or indirectly suppress the functional activity of the FAM25C protein. Compounds like LY294002 and Wortmannin exemplify direct inhibition by targeting the PI3K pathway, a critical cascade influencing multiple cellular processes including those in which FAM25C might be engaged. The inhibition of PI3K leads to the blockade of the downstream Akt pathway, which could be pivotal for FAM25C signaling related to cell survival and proliferation. Similarly, mTOR inhibitor Rapamycin also plays a significant role by suppressing cell growth and proliferation, possibly affecting FAM25C activities linked with such processes. These inhibitors collectively demonstrate how disruption of upstream signaling entities can attenuate the functional dynamics of FAM25C, by terminating pathways that are potentially vital for its activation or stability.
The inhibitors like PD98059, U0126, and SB203580 exemplify an indirect class of inhibition by targeting kinases such as MEK and p38 MAP kinase, which are upstream of pathways that FAM25C may utilize for its signaling mechanism. By impeding the MEK/ERK and p38 MAPK pathways, these inhibitors disrupt the flow of cellular signals that could be essential for the functional expression of FAM25C, thus indirectly dampening its activity. In addition, compounds such as PP2 and Dasatinib, which inhibit Src family kinases and Bcr-Abl, respectively, might also affect FAM25C indirectly by altering signaling pathways that regulate or interact with FAM25C. Furthermore, Go6983's inhibition of PKC could affect FAM25C if its activity is contingent upon PKC-mediated signaling pathways. Gefitinib's ability to inhibit EGFR tyrosine kinase could also hinder pathways where FAM25C is modulated by EGFR signaling, while Y-27632, as a ROCK inhibitor, might undermine FAM25C's potential involvement in cytoskeletal organization. Thus, the landscape of FAM25C inhibitors is characterized by a multifaceted approach to dampening the protein's activity through the strategic blockade of various signaling routes pertinent to its functional expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which leads to the blockade of Akt phosphorylation and activation. Since FAM25C is associated with cellular signaling, the inhibition of PI3K could prevent downstream signaling required for FAM25C-mediated processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of mitogen-activated protein kinase kinase (MEK), which indirectly inhibits the ERK pathway. As FAM25C is involved in cellular signaling, inhibiting MEK would disrupt ERK pathway signaling, potentially reducing FAM25C activity as it may rely on this pathway for its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAP kinase inhibitor that interrupts the p38 signaling pathway. If FAM25C's activity is linked with the p38 pathway, this compound would indirectly inhibit the functional activity of FAM25C by blocking signals that may be necessary for its activation or stabilization. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that would interfere with the JNK signaling pathway. Given that FAM25C is a signaling protein, the inhibition of JNK could lead to a reduction in FAM25C activity if JNK signaling contributes to its functional state. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor, similar to LY294002, but with a different binding mechanism. It also prevents Akt activation and would disrupt any PI3K-dependent pathways that contribute to FAM25C activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress cell growth and proliferation. Since mTOR signaling affects many cellular processes, inhibition of mTOR could decrease FAM25C's functionality if it is involved in pathways linked to cell growth where mTOR's activity is necessary. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that blocks ERK phosphorylation and activation. By disrupting the MEK/ERK pathway, U0126 could indirectly decrease the functional activity of FAM25C if it relies on this pathway for its signal transduction. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A Src family kinase inhibitor, which may influence multiple signaling pathways. By inhibiting Src kinases, PP2 could indirectly affect FAM25C activity if FAM25C operates downstream or is modulated by Src kinase signaling. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A broad-spectrum protein kinase C (PKC) inhibitor. Since PKC is involved in various signaling pathways, inhibiting PKC could potentially reduce FAM25C activity if it is regulated by PKC-mediated signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR tyrosine kinase inhibitor that could disrupt signaling pathways where FAM25C is involved if FAM25C activity is modulated by EGFR signaling. | ||||||